Showing 3521-3530 of 5956 results for "".
- EU Wraps Up Advanced Talks With Moderna for COVID-19 Vaccine Supply Dealhttps://modernod.com/news/eu-wraps-up-advanced-talks-with-moderna-for-covid-19-vaccine-supply-deal/2478195/The European Commission said Monday that it concluded exploratory talks with Moderna for an initial purchase of 80 million doses of the company’s mRNA vaccine candidate against SARS-CoV-2. The contractual framework would also provide an option for EU member states to purchase an additional
- Supreme Court to Hear Arguments on Pivotal Case That Decides Fate of ACA After Electionhttps://modernod.com/news/supreme-court-to-hear-arguments-on-pivotal-case-that-decides-fate-of-aca-after-election/2478180/The Supreme Court will hear oral arguments in a lawsuit over the constitutionality of the Affordable Care Act (ACA) on November 10, a week after the presidential election, according to a FierceHealthcare
- How COVID-19 is Shaking Up Medical Education—For Goodhttps://modernod.com/news/how-covid-19-is-shaking-up-medical-education-for-good/2478168/With COVID-19 shows no signs of letting up soon, leaders at medical schools are adapting their plans for education in the fall to meet the new demands of the pandemic, according to a FierceHealthcare report. That means going digital in an unprecedented way—both in terms of classe
- TearClear Raises $22M in Series B Fundinghttps://modernod.com/news/tearclear-raises-22m-in-series-b-funding/2478158/TearClear announced it has raised $22 million in a Series B funding round. The company intends to use the funds to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications. Led by Chief Executive Officer Robert Dempsey, T
- CooperVision Acquires GP Specialists, Expanding Specialty EyeCare Business and Ortho-K Optionshttps://modernod.com/news/coopervision-acquires-gp-specialists-expanding-specialty-eyecare-business-and-ortho-k-options/2478137/CooperVision has acquired C&E GP Specialists, a customized orthokeratology contact lens manufacturer and distributor. The move expands CooperVision’s Specialty eye care business. Terms of the deal were not disclosed. “CooperVision is committed to providing eye care professionals
- AAO: Planned Medicare Cuts Deal Heavy Blow to Nation’s Ophthalmologistshttps://modernod.com/news/aao-planned-medicare-cuts-deal-heavy-blow-to-nations-ophthalmologists/2478132/The American Academy of Ophthalmology (AAO) released a statement opposing the Centers for Medicare & Medicaid Services (CMS) proposed annual Physician Fee Schedule and Quality Payment Program
- Some Providers Face Daunting Repayment Deadline for Medicare Advance Loanshttps://modernod.com/news/some-providers-face-daunting-repayment-deadline-for-medicare-advance-loans/2478108/Starting this month, some providers are facing the prospect of their Medicare payments garnished to repay COVID-19 loans, according to a FierceHealthcare
- Pfizer, BioNTech Begin Phase 2/3 Coronavirus Vaccine Studyhttps://modernod.com/news/pfizer-biontech-pick-bnt162b2-to-advance-into-phase-2-3-coronavirus-vaccine-study/2478084/Pfizer and partner BioNTech said they have decided to advance the nucleoside-modified mRNA vaccine candidate BNT162b2 into phase 2/3 testing. The vaccine, to be trialed at the 30-mcg dose as part of a two-dose regimen, encodes for an optimized SARS-CoV-2 full-length spike glycoprotein, which the
- Algorithm Compares Risk of Cancelled Ophthalmology Appointments Against COVID-19https://modernod.com/news/algorithm-compares-risk-of-cancelled-ophthalmology-appointments-against-covid-19/2478075/The COVID-19 pandemic has forced many ophthalmologists across the US to cancel potentially necessary eye examinations with patients since March. A team, led by Nikhil K. Bommakanti, MD, W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, developed a f
- Moderna Loses US Patent Challenge That Could Affect COVID-19 Vaccinehttps://modernod.com/news/moderna-loses-us-patent-challenge-that-could-affect-covid-19-vaccine/2478072/Shares in Moderna fell as much as 10% Thursday after the company failed in an attempt to invalidate a US patent on vaccine technology held by Arbutus Biopharma. SVB Leerink analyst Mani Foroohar suggested the decision by an administrative court run by the US Patent and Trademark Office opens the